<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826149</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1160053</org_study_id>
    <nct_id>NCT01826149</nct_id>
  </id_info>
  <brief_title>Propofol Effects on Mitral Valve Annular Velocity</brief_title>
  <official_title>The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is primarily to determine the effects of propofol at different
      concentration on the mitral valve annulus by using Tissue Doppler Imaging
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effects of different concentration of propofol
      on patients who are undergoing cardiac surgery. The patients will receive infusion
      remifentanil 0.5mcg/kg/min with different target-site propofol concentration namely 1.0ng/ml,
      2.0ng/ml and 3.0ng/ml. Tissue Doppler Imaging by transesophageal echocardiography will be
      done to assess the changes in cardiac function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of systolic mitral valve annular velocity (S')</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
    <description>To examine the effect of Propofol at different effect-site concentration ( 1.0 ng/ml, 2.0 ng/ml and 3.0 ng/ml) on S' (systolic mitral valve annular velocity) during remifentanil-based anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early diastolic mitral valve annular velocity (e')</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late diastolic (atrial contractile) mitral valve annular velocity (a')</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ejection fraction</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phenylephrine infusion rate</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Propofol 1.0mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 2.0mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 3.0mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 1.0mcg</intervention_name>
    <description>Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.</description>
    <arm_group_label>Propofol 1.0mcg</arm_group_label>
    <other_name>Fresofol (2% propofol, Fresinius Kabi)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 2.0mcg</intervention_name>
    <description>Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.</description>
    <arm_group_label>Propofol 2.0mcg</arm_group_label>
    <other_name>Fresofol (2% propofol, Fresinius Kabi)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 3.0mcg</intervention_name>
    <description>Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion</description>
    <arm_group_label>Propofol 3.0mcg</arm_group_label>
    <other_name>Fresofol (2% propofol, Fresinius Kabi)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients undergoing cardiac surgery

        Exclusion Criteria:

        low ejection fraction &lt; 50% on transthoracic echocardiography atrial fibrillation pacemaker
        pericardial and infiltrative myocardial disease mitral annular calcification, surgical
        rings, prosthetic mitral valve lateral left ventricular wall motion abnormality oesophageal
        abnormality history of extensive radiation to the mediastinum upper gastrointestinal
        bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-yop Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center, Seoul, Korea, Republic of</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 15, 2016</submitted>
    <returned>January 11, 2017</returned>
    <submitted>January 13, 2017</submitted>
    <returned>March 3, 2017</returned>
    <submitted>March 19, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

